Peter J. O'Dwyer
Peter O'Dwyer is a GI oncologist who co-leads ECOG-ACRIN, one of the NCI's national trial networks.
Medical oncologist with a background in pharmacology and early drug development. Co-chairs ECOG-ACRIN with Mitchell Schnall and directs the Penn Developmental Therapeutics Program.
| Title | Journal | Year |
|---|---|---|
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Journal of Clinical Oncology | 2023 |
| Etoposide (VP-16-213). Current status of an active anticancer drug | New England Journal of Medicine | 1985 |
Pages like this
not linked directly; found by shared links- PersonRobert H. Vonderheide
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
- PersonMitchell D. Schnall
Shares ECOG-ACRIN Cancer Research Group, Abramson Cancer Center, University of Pennsylvania.
- InstitutionUniversity of Wisconsin Carbone Cancer Center
- PersonSusan M. Domchek
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
- PathwayAutophagy
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
- PathwayMicrobiome–tumour interactions
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma, Colorectal cancer.